ELAN INVESTIGATION NOTICE: BFA Law Alerts Investors that it is Investigating Elanco (NYSE: ELAN) for Securities Fraud; Investors who Suffered Losses are Urged to Contact the Firm

If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. With respect to these treatments, the company stated that the FDA "has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June [2024]." However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Ze ...